-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, USYeEso6CYYFMlL8jSN14dl8CEN+THsHv5+yhyq+uv3NwUC31pQEwwQJrVtOf577 9+BMGimvRcbsTd05XOy3ZA== /in/edgar/work/20000605/0000895345-00-000318/0000895345-00-000318.txt : 20000919 0000895345-00-000318.hdr.sgml : 20000919 ACCESSION NUMBER: 0000895345-00-000318 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20000605 GROUP MEMBERS: MERCK & CO INC GROUP MEMBERS: MERCK-MEDCO MANAGED CARE, L.L.C. GROUP MEMBERS: PV ACQUISITION CORP. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROVANTAGE HEALTH SERVICES INC CENTRAL INDEX KEY: 0001072471 STANDARD INDUSTRIAL CLASSIFICATION: [8093 ] IRS NUMBER: 541508848 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-58191 FILM NUMBER: 649123 BUSINESS ADDRESS: STREET 1: 13555 BISHOPS COURT STREET 2: SUITE 201 CITY: BROOKFIELD STATE: WI ZIP: 53005 BUSINESS PHONE: 4147844600 MAIL ADDRESS: STREET 1: 13555 BISHOPS COURT STREET 2: SUITE 201 CITY: BROOKFIELD STATE: WI ZIP: 53005 FORMER COMPANY: FORMER CONFORMED NAME: PROVANTAGE INC DATE OF NAME CHANGE: 19981021 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROVANTAGE HEALTH SERVICES INC CENTRAL INDEX KEY: 0001072471 STANDARD INDUSTRIAL CLASSIFICATION: [8093 ] IRS NUMBER: 541508848 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: SEC FILE NUMBER: 005-58191 FILM NUMBER: 649124 BUSINESS ADDRESS: STREET 1: 13555 BISHOPS COURT STREET 2: SUITE 201 CITY: BROOKFIELD STATE: WI ZIP: 53005 BUSINESS PHONE: 4147844600 MAIL ADDRESS: STREET 1: 13555 BISHOPS COURT STREET 2: SUITE 201 CITY: BROOKFIELD STATE: WI ZIP: 53005 FORMER COMPANY: FORMER CONFORMED NAME: PROVANTAGE INC DATE OF NAME CHANGE: 19981021 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERCK & CO INC CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084234044 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERCK & CO INC CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084234044 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 SC TO-T/A 1 0001.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------------------- AMENDMENT NO. 2 OF SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 AND AMENDMENT NO. 2 TO SCHEDULE 13D Under the Securities Exchange Act of 1934 ---------------------------- PROVANTAGE HEALTH SERVICES, INC. (Name of Subject Company (Issuer)) MERCK & CO., INC. (OFFEROR PARENT) PV ACQUISITION CORP. (OFFEROR) MERCK-MEDCO MANAGED CARE, L.L.C. (PARENT SUBSIDIARY) (Names of Filing Persons (identifying status as offeror, issuer or other person)) ---------------------------- Common Stock, Par Value $0.01 Per Share (Including the Associated Rights) (Title of Class of Securities) 743725 10 3 (CUSIP Number of Class of Securities) ---------------------------- CELIA A. COLBERT PV ACQUISITION CORP. C/O MERCK & CO., INC. ONE MERCK DRIVE WHITEHOUSE STATION, NEW JERSEY 08889 (908) 423-1000 (Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons) WITH A COPY TO: GARY P. COOPERSTEIN, ESQ. FRIED, FRANK, HARRIS, SHRIVER & JACOBSON ONE NEW YORK PLAZA NEW YORK, NEW YORK 10004 (212) 859-8000 CALCULATION OF FILING FEE - ---------------------------------------------------------------------------- Transaction Valuation: * Amount of filing fee: $226,724,985 $45,345 - ---------------------------------------------------------------------------- * For purposes of calculating fee only. This amount is based on a per share offering price of $12.25 for 18,150,000 shares of common stock and for options to purchase 358,162 options with strike prices lower than $12.25 that may become exercisable before or during a subsequent offer period, if any. Pursuant to the Agreement and Plan of Merger, dated as of May 4, 2000, by and among ProVantage Health Services, Inc. (the "Company"), Merck & Co., Inc. and PV Acquisition Corp. (together, the "Bidders"), the Company represented to the Bidders that, as of such date, it had 18,150,000 shares of common stock issued and outstanding and 873,309 shares of common stock reserved for issuance upon exercise of outstanding stock options, none of which are currently exercisable and all of which will become exercisable before or during a subsequent offer period, if any. The amount of the filing fee, calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, equals 1/50 of one percent of the aggregate of the cash offered by the Bidder. [X] Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Amount Previously Paid: $226,724,985 Form or Registration No.: Schedule TO Filing Party: Merck & Co., Inc. and PV Acquisition Corp. Date Filed: May 10, 2000 [ ] Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates: [X] third-party offer subject to Rule 14d-1. [ ] issuer tender offer subject to Rule 13e-4. [ ] going-private transactions subject to Rule 13e-3. [X] amendment to Schedule 13D under Rule 13d-2. Check the following box if the filing is a final amendment reporting the results of the tender offer: SCHEDULE 13D CUSIP No. 743725-10-3 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON MERCK & CO., INC. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 SOURCE OF FUNDS (See instructions) WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] 6 CITIZENSHIP OR PLACE OF ORGANIZATION NEW JERSEY NUMBER OF 7 SOLE VOTING POWER SHARES -0- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 11,710,000(1) REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH -0- 10 SHARED DISPOSITIVE POWER -0- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,710,000(1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) [ ] EXCLUDES CERTAIN SHARES (See instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 64.5% 14 TYPE OF REPORTING PERSON (See instructions) CO (1) See Item 5 of Schedule TO, filed by Merck & Co., Inc. and PV Acquisition Corp. on May 10, 2000, and Items 4 and 5 of Schedule 13D, filed by Merck & Co., Inc., Merck-Medco Managed Care, L.L.C. and PV Acquisition Corp. on May 10, 2000. SCHEDULE 13D CUSIP No. 743725-10-3 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON MERCK-MEDCO MANAGED CARE, L.L.C. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 SOURCE OF FUNDS (See instructions) AF 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF 7 SOLE VOTING POWER SHARES -0- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 11,710,000(1) REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH -0- 10 SHARED DISPOSITIVE POWER -0- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,710,000(1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) [ ] EXCLUDES CERTAIN SHARES (See instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 64.5% 14 TYPE OF REPORTING PERSON (See instructions) OO (1) See Item 5 of Schedule TO, filed by Merck & Co., Inc. and PV Acquisition Corp. on May 10, 2000, and Items 4 and 5 of Schedule 13D, filed by Merck & Co., Inc., Merck-Medco Managed Care, L.L.C. and PV Acquisition Corp. on May 10, 2000. SCHEDULE 13D CUSIP No. 743725-10-3 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON PV ACQUISITION CORP. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 SOURCE OF FUNDS (See instructions) AF 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE NUMBER OF 7 SOLE VOTING POWER SHARES -0- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 11,710,000(1) REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH -0- 10 SHARED DISPOSITIVE POWER -0- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,710,000(1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) [ ] EXCLUDES CERTAIN SHARES (See instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 64.5% 14 TYPE OF REPORTING PERSON (See instructions) CO (1) See Item 5 of Schedule TO, filed by Merck & Co., Inc. and PV Acquisition Corp. on May 10, 2000, and Items 4 and 5 of Schedule 13D, filed by Merck & Co., Inc., Merck-Medco Managed Care, L.L.C. and PV Acquisition Corp. on May 10, 2000. This Amendment No. 2, filed on June 5, 2000 to the Schedules TO and 13D filed on May 10, 2000, as amended by Amendment No. 1 to those Schedules, relates to the offer by PV Acquisition Corp., a Delaware corporation and indirect wholly owned subsidiary of Merck & Co., Inc., a New Jersey corporation ("Parent"), to purchase all of the outstanding shares of Common Stock, par value $0.01 per share (the "Shares"), of ProVantage Health Services, Inc., a Delaware corporation (the "Company"), at a price of $12.25 per Share, net to the seller in cash and without interest thereon, on the terms and subject to the conditions set forth in the Offer to Purchase, dated May 10, 2000 (the "Offer to Purchase"), and the related Letter of Transmittal, which, together with the Offer to Purchase, constitutes the "Offer". ITEM 11. ADDITIONAL INFORMATION Item 11 is hereby amended to add the following information to Section 16 of the Offer to Purchase: On or about May 31, 2000, counsel to the Board of Directors of Parent received a letter from Milberg Weiss Bershad Hynes & Lerach LLP, counsel to the named plaintiff in the purported class action, addressed to it and the Boards of Directors of the Company and ShopKo Stores, Inc. asserting that the "SEC forms 14D-1 [Schedule TO] and [Schedule] 14D-9...are false and misleading in that they fail to disclose material information rendering such documents false and misleading." The letter is attached as Exhibit (a)(1)(J) hereto and is incorporated herein by reference. This summary is qualified in its entirety by reference to Exhibit (a)(1)(J) hereto. Parent and Offeror believe these assertions are without merit. ITEM 12. EXHIBITS Item 12 is hereby amended to add the following exhibit: (a)(1)(J) -Letter from Milberg Weiss Bershad Hynes & Lerach LLP dated May 31, 2000. SIGNATURES After due inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. June 5, 2000 MERCK & CO., INC. By: /s/ Judy C. Lewent ------------------------------------ Name: Judy C. Lewent Title: Senior Vice President and Chief Financial Officer PV ACQUISITION CORP. By: /s/ Judy C. Lewent ------------------------------------ Name: Judy C. Lewent Title: President MERCK-MEDCO MANAGED CARE, L.L.C. By: /s/ Richard T. Clark ------------------------------------ Name: Richard T. Clark Title: President EXHIBIT INDEX ------------- EXHIBIT ------- (a)(1)(J) -Letter from Milberg Weiss Bershad Hynes & Lerach LLP dated May 31, 2000. EX-99.(A)(1)(J) 2 0002.txt Exhibit (a)(1)(J) [LETTERHEAD OF MILBERG WEISS BERSHAD HYNES & LERACH LLP] May 31, 2000 VIA FACSIMILE ------------- Board of Directors of Shopke Board of Directors of ProVantage c/o Nancy Senate FOLEY & LARDNER 150 East Gilman Street Madison, WI 53701-1497 Board of Directors of Merck c/o Gary P. Cooperstein FRIED, FRANK, HARRIS, SHRIVER & JACOBSON One New York Plaza New York, NY 10004 Re: ProVantage Shareholder Litigation Dear Board Members: The Tender Offer Documents issued in connection with the sale of ProVantage, Inc., including the SEC forms 14D-1 and 14-9 ("Documents") are false and misleading in that they fail to disclose material information rendering such documents false and misleading. The Documents conceal material information relating to the motivations and benefits which will be obtained by the Board Members of ProVantage and Shopko upon consummation of the transaction. For example, the Documents fail to disclose the fact that Shopko's 61% ownership interest in ProVantage is highly illiquid. Though Shopko's ownership stake was no longer subject to the Rule 144 time restrictions, it was subject to the Rule 144 volume restrictions which, as a practical matter, effectively precluded it from selling its interest in ProVantage for years at anywhere near the price obtained in this transaction. Unlike Shopko, our client and the other public stockholders of ProVantage were not so disadvantaged as they have never faced the illiquidity issues faced by Shopko. The Documents also conceal the benefits that will be reaped by Girard, Kramer, Wolf and Podany upon consummation of the Tender Offer by virtue of their relationship with Shopko. Furthermore, the Documents conveniently omit from the "Background" section that on February 29, 2000, one day after Merck submitted an offer to purchase the company, ProVantage granted options to key officers which have a post-exercise price value of $1,450,000. The Documents are fraught with material omissions and misstatements. Merck must refrain from purchasing ProVantage shares from ProVantage's shareholders in the Tender Offer until it makes adequate disclosure of all material information to ProVantage shareholders. Plaintiffs' concerns with the Tender Offer documents are many and given the defects in these materials, our client immediately attempted to contact Nancy Senate, Shopko's and ProVantage's counsel, to apprise her of the necessity of correcting these problems and/or refraining from consummating the Tender Offer, as proposed. She has not responded. We view these issues as extremely important. The Tender Offer is scheduled to close on June 14, 2000. Accordingly, the necessary corrections must be provided to ProVantage shareholders on or before June 5, 2000. If we do not hear from you on or before Thursday, June 1, 2000, we will arrange to take the necessary steps to protect ProVantage's public stockholders. Very truly yours, /s/ Randall H. Steinmeyer RANDALL H. STEINMEYER RHS:krj -----END PRIVACY-ENHANCED MESSAGE-----